RxDoctor Payments Data

Gregory Levickas, MD

Internal Medicine · Catonsville, MDNPI 1891739744

Payments from drug & device makers

$829in general payments, 2019–2025

Across 58 payments — averaging $14.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$176
  • Novartis$107
  • Exact Sciences$72
  • Boehringer Ingelheim$70
  • AbbVie$60
  • Pfizer$56
  • plus $289 from 13 others

What the payments were for

  • Food & beverage$829100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$829 in reported general payments places this provider in the 70th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$228,360
Medicare patients
640
Services billed
2,704

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide175$177,362
EliquisApixaban166$156,476
JardianceEmpagliflozin80$89,840
FarxigaDapagliflozin Propanediol62$75,726
XareltoRivaroxaban48$63,000
CreonLipase/Protease/Amylase27$56,404
JanuviaSitagliptin Phosphate33$30,624
TrulicityDulaglutide23$29,861
RexultiBrexpiprazole13$19,183
MounjaroTirzepatide19$18,933
Tresiba Flextouch U-200Insulin Degludec18$18,609
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$15,459
Breo ElliptaFluticasone/Vilanterol24$14,350
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr30$13,798
Atorvastatin Calcium776$11,880

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$176$177,362175 claims
PfizerEliquis$56$156,476166 claims
Boehringer IngelheimJardiance$70$89,84080 claims
AstraZenecaFarxiga$53$75,72662 claims
Johnson & JohnsonXarelto$26$63,00048 claims
AbbVieCreon$60$56,40427 claims
Lilly USA, LLCTrulicity, Mounjaro$38$48,79442 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$14$43,60773 claims
MerckJanuvia$11$30,62433 claims
Astellas Pharma US IncMyrbetriq$22$5,63812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Catonsville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →